TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Presence of Covid-19
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Duration of persistent virus isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Achievement of durability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Socket Comfort Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Prosthetic Evaluation Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plantar sensation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change of Left internal mammary artery internal diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Jawline Contour Rating Scale (JCRS) responder rate
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Complete remission (CR)/CR with partial hematologic recovery (CRh)/CR with incomplete hematologic recovery (CRi) with negative MRD detected by flow cytometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CR/CRh/CRi with negative MRD detected by NGS (next-generation sequencing)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in number of patient risky drinking days
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Child Compliance and Parent Interaction
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Rate of Definite Myocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of Possible Myocarditis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of participants who complete the follow-up assessment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Deprescribing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in pain interference
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Proportion of Participants With Captured Hypoglycaemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Spontaneous Breathing Trial
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Nutritional autonomy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: rate of retention in care
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Concordance of heart failure decompensation detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of participants requiring blood transfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Maximum concentration (Cmax) of TNM002
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with an increase of serum TNM002-specific anti-tetanus neutralizing antibody titers (ΔTiters) ≥ 0.01 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects with serum anti-tetanus antibody titers ≥ 0.1 IU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mechanical axis deviation (MAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Femoral anteversion (FA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medial proximal tibial angle (MPTA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ego-Disengagement scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Cortical activity - change in gamma band power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cortical activity - change in alpha band power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Quality of life of patient
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Removal of nasogastric tubes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Olfactory Function Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative vascularization assessed by fluorescence intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Academic Performance (Score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Invasive urodynamic study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Safety of acute t-VNS assessed via orthostatic challenge
Endpoint domain: Adverse events/effects
Primary endpoint: Structured assessments of adverse events (AEs) and serious adverse events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of acute t-VNS
Endpoint domain: Adverse events/effects
Primary endpoint: Performance (% of correct classification)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Richard-Campbell Sleep Scale (RCSS)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Tetanic Fade Ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ability to initiate and take an independent, voluntary step
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Pain at 15th day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline maximum mouth opening at 15th day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Management of large common bile duct stones
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Visual Field MD at 12 Months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission rate of intolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients with modified Rankin Score 0 to 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volumetric and functional feasibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Region of interest quantifiability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality rate in liver transplantation
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of liver cancer or decompensated cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of dose limiting toxicities of tegavivint
Endpoint domain: Adverse events/effects
Primary endpoint: Frequency of adverse events attributable to tegavivint
Endpoint domain: Adverse events/effects
Primary endpoint: Area under the drug concentration curve of tegavivint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymph node detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients without Serious Adverse Events (SAEs) and Serious Adverse Device Effects (SADEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants without Freedom from clinically-driven target lesion revascularization (CD-TLR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Bone marrow environment modulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of time in range (TIR 70-180 mg/dL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Completion of Medication Abortion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of Adverse Events (AEs) and Serious Adverse Events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Psoriasis severity score (TES)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Combined Pain Severity and Interference Scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Safety of avutometinib
Endpoint domain: Adverse events/effects
Primary endpoint: 1-week psychometric reliability of Aperiodic Spectral Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in pain intensity level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressionsymptom scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FD symptom scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chinese Medicine Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymphocyte subset analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Prevalence of antibodies against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Number of Participants With All Cause Hospitalization Visits: 18-64 Years Old
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants With All Cause Hospitalization Visits: >=65 Years Old
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants With Composite Coronavirus Disease (COVID-19)-Related Hospitalization, Emergency Department or Urgent Care Visits
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Concentration of blood glucose in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of total cholesterol in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retrieval rate of the HydroMARK Plus clip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Objective quantification of pain levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of respiratory illnesses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Mobility of the big toe joint
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Cutaneous vascular conductance (CVC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Corneal hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of hemidiaphragmatic paralysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Executive Function from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in processing speed from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Detection of hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: State-trait Anxiety Inventory
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Post operative muscle weakness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Percentage of Bone Formation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Severity of Dizziness
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of all TEAEs
Endpoint domain: Adverse events/effects
Primary endpoint: abdominal skin fold
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: fat thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percent of days using non-combustible product
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Domain Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Plasma Triglyceride Concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of confirmed Herpes Zoster cases
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of subjects with a ≥ 2-point improvement on the FWS score at maximum frown
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of subclinical ABMR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the Fugl-Meyer Assessment Scale for Upper Extremity (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence rate one year post operative
Endpoint domain: Mortality/survival
Primary endpoint: Impact of neck pain on daily life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in MAPSE measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Resting State fMRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in task-based fMRI: cognitive task with emotional distractors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in task-based fMRI: monetary reward and punishment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: baro receptor sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: target cNF volume reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: adverse events and serious adverse events assessments
Endpoint domain: Adverse events/effects
Primary endpoint: Change in absolute weight (Kg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants achieving 5 percent total weight loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dose in CFU required for systemic Salmonellosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Incidence of symptomatic SDH recurrence/progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: olfactory dysfunction improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: arrhythmia
Endpoint domain: Adverse events/effects
Primary endpoint: Echocardiogram LVEF
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hair Growth Index (HGI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hair Growth Satisfaction Scale (HGSS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Investigator Global Assessment of Photography
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Birth experience
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Treatment related-adverse events counting
Endpoint domain: Adverse events/effects
Primary endpoint: Threshold of the psychometric function (behavioural)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Slope of psychometric function (behavioural)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG (event-related potentials)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: EEG (frequency tagging)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Sleep Quality Assessment
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Aβburden PET imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Self-Efficacy Scale in Health Management
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: change in percent of participants who are not susceptible to future vaping
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in susceptibility score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Anisotropy score after tractography MRI sequence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Correlation between anisotropy coefficient and ACL lesion state
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change of the IKDC scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the joint position sense measure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic performance of blood biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Awareness level
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in thoracic kyphosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: blood neurofilament light chain (NfL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: blood and cerebrospinal fluid (CSF) biomarker of BBB integrity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete Spontaneous Bowel Movement (CSBM) response rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Volume of breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nutritional outcomes
Primary endpoint: Microbiota of breast milk
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended dose for phase II (RP2D)
Endpoint domain: Adverse events/effects
Primary endpoint: Dimensional alveolar bone changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of new formed bone tissue
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Evaluation of Implant Stability Quotient (ISQ)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Proportion of nulliparous with positive urine test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Moderate and severe anemia during the last antenatal care visit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: P. falciparum infection at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in accuracy of naming untrained pictures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Significant laboratory abnormalities
Endpoint domain: Adverse events/effects
Primary endpoint: Joint Range of Motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: The visual analogue scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of enrollment in clinical research
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of participants remaining until completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in disease-specific quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Modified Fatigue Impact Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Acceptability
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Cooling rate at 0.5 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body temperature at 0.5 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bruininks-Oseretsky Test of motor function Proficiency-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Independence Measure for Children
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of patients using currently CHCs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of patients having used CHCs
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Perception about the impact of CHCs on favoring/contrasting specific cancer onset
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total Acceleration of Hand Movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Muscle Activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neural Activation in Primary Motor Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Neural Activation in Supplementary Motor Cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient associated catastrophic costs
Endpoint domain: Resource use
Primary endpoint: safe apnoea times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients that experience an Adverse Device Effect (ADE)
Endpoint domain: Adverse events/effects
Primary endpoint: Ability of EARP System to alert the surgeon to nerve irritation during surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence and severity of all reported adverse events
Endpoint domain: Adverse events/effects